Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.

Artemisinin based combination therapies (ACTs) are currently recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated malaria in all malaria endemic countries including Tanzania, that adopted the policy in 2007. ACTs have proven to be highly efficacious in different parts of the world with different malaria endemicity. Artemisinins clear asexual parasites rapidly and they are also potent against P. falciparum gametocytes, hence reducing disease transmission and spread of drug resistance. Nonetheless, a report in Kenya shows an increase in proportion of patients with parasitaemia on day 1. Most recently, resistance against artemisinins has been confirmed in four countries of South-East Asia, and it may spread to Africa.

In order to safeguard ACTs life span, WHO recommends all suspected malaria cases to be confirmed with parasitological diagnosis, followed by prompt treatment with effective antimalarials. It also emphasizes on the need to conduct efficacy studies for the first and second line antimalarial treatments after every two years so as to be able to detect resistance early on its course. Therefore, based on this notion, this study aimed to assess the therapeutic efficacy of Artemether/Lumefantrine among children with uncomplicated falciparum malaria in Bagamoyo district, five years after its wide scale use in Tanzania.

Inclusion criteria

• Mono-infection with P. falciparum
• Parasitaemia level of 2000 - 200,000/μL
• Absence of danger signs or signs of severe malaria
• Axillary temperature ≥ 37.5°C or history of fever 24 hours prior to coming to the facility
• Absence of other concomitant infections like pneumonia which can cause fever
• No use of antimalarial drug two weeks prior to the study
• Consent to comply to the protocol.

Exclusion criteria

• Presence of general danger signs or signs of severe falciparum malaria
• Severe malnutrition
• Febrile condition due to diseases other than malaria, such as measles, acute lower respiratory infection or other known chronic diseases
• Regular medication which might interfere with antimalarial pharmacokinetics
• History of hypersensitivity reactions or contraindications to any medicine being used in the trial.